Clinical Trial Compensation Claims

1. Introduction

Clinical Trial Compensation Claims are legal claims for monetary compensation, medical treatment, rehabilitation, or other remedies arising when a participant suffers injury, disability, adverse health consequences, or death in connection with a clinical trial.

In India, clinical-trial compensation has a particularly important statutory foundation under the New Drugs and Clinical Trials Rules, 2019 (NDCTR). The Rules specifically provide for compensation in cases of clinical-trial-related injury or death and place the primary financial responsibility on the sponsor or its representative.

A crucial point is that clinical-trial compensation is not necessarily dependent upon proving ordinary medical negligence in the traditional tort sense. The regulatory framework creates a specialized mechanism for determining whether an injury or death is clinical-trial related and, if so, for determining compensation.

At the same time, general principles concerning informed consent, medical negligence, patient rights, Article 21, consumer protection and public-law compensation remain highly relevant.

Important: Reported Indian judicial decisions directly deciding clinical-trial compensation claims are comparatively limited. Consequently, the leading authorities include both (i) cases directly or closely connected with clinical research/medical consent and (ii) general medical-compensation cases whose principles apply to clinical-trial injuries.

2. Meaning of a Clinical Trial

A clinical trial is a systematic investigation involving human participants to evaluate a medical intervention, such as:

• a new drug;
• vaccine;
• biological product;
• medical device;
• new therapeutic method;
• investigational medicinal product.

Clinical trials are normally conducted according to an approved protocol and under the supervision of regulatory authorities and an Ethics Committee.

Because participants may be exposed to risks that would not exist in ordinary treatment, the law imposes enhanced obligations concerning:

• informed consent;
• safety monitoring;
• medical management;
• adverse-event reporting;
• compensation;
• insurance/financial protection;
• confidentiality;
• ethical review.

3. Legal Framework in India

The principal framework is the:

New Drugs and Clinical Trials Rules, 2019

The Rules contain a dedicated Chapter VI — Compensation.

Rule 39 provides that where a trial subject dies during a clinical trial or a bioavailability/bioequivalence study involving a new drug or investigational new drug, the legal heir is to receive financial compensation from the sponsor or its representative according to the prescribed procedure.

The regulatory framework also requires the sponsor to bear expenses relating to medical management and financial compensation for qualifying clinical-trial injury or death.

4. Who Can Claim Compensation?

Depending on the circumstances, compensation may be payable to:

A. Injured participant

Where the participant suffers:

• temporary injury;
• permanent disability;
• other qualifying injury.

B. Legal heirs

Where the participant dies as a result of a clinical-trial-related event.

C. In certain situations, the participant's representative

Where the participant lacks legal capacity, appropriate representation mechanisms may apply.

The regulatory system distinguishes between compensation for the participant and compensation payable to the nominee/legal heirs in a death case.

5. When Is an Injury Considered Clinical-Trial Related?

This is one of the most important questions.

Under the clinical-trial compensation framework, qualifying circumstances include injury or death resulting from matters such as:

1. adverse effect of the investigational product;
2. violation of the approved protocol;
3. scientific misconduct;
4. negligence of the sponsor, representative or investigator;
5. failure of the investigational product to provide its intended therapeutic effect in circumstances covered by the Rules;
6. use of placebo in specified circumstances;
7. adverse effects of concomitant medication required by the protocol;
8. injury to a child in utero because of parental participation;
9. clinical-trial procedures themselves. 

This is extremely important.

The claim is therefore broader than a conventional negligence claim.

6. Compensation Is Not the Same as Ordinary Medical Negligence

There are two potentially different legal routes.

Route 1 — Clinical-trial regulatory compensation

The participant establishes that the injury/death falls within the regulatory definition of clinical-trial-related injury or death.

Route 2 — Ordinary legal liability

The claimant may potentially pursue remedies based upon:

• negligence;
• deficiency in service;
• breach of consent requirements;
• constitutional rights;
• tort law;
• consumer law;
• contractual obligations.

Therefore:

Failure to establish conventional medical negligence does not necessarily mean that every clinical-trial compensation claim automatically fails.

The regulatory scheme has its own criteria.

7. Medical Management and Compensation Are Separate

A very important principle is that medical treatment and compensation are not substitutes for each other.

Where an injury occurs, the participant may be entitled to appropriate medical management, while financial compensation may additionally be payable where the injury is determined to be clinical-trial related.

The regulatory framework expressly places expenses for medical management and financial compensation on the sponsor.

Thus:

Medical treatment

Financial compensation

may both be required.

8. Compensation for Death

The NDCTR provides a specific formula for determining compensation in cases of clinical-trial-related death.

The Seventh Schedule provides:

Compensation = (B × F × R) / 99.37

where:

• B = Base amount of ₹8 lakh
• F = age-related factor
• R = risk factor

The risk factor reflects matters such as:

• seriousness of disease;
• severity;
• co-morbidities;
• duration of disease;
• risk level of the participant.

The prescribed risk factor ranges from 0.5 to 4.0. For certain extremely high-mortality situations, the Rules prescribe a fixed amount.

9. Compensation for Non-Fatal Injury

The Rules distinguish between different types of injury.

Permanent disability

Financial compensation may be payable according to the prescribed framework.

Temporary/non-permanent injury

The compensation is linked to the participant's loss of wages, as provided by the applicable formula/framework.

Thus, compensation is not necessarily a single fixed amount for every participant.

10. Factors Relevant to Compensation

The assessment may involve:

• age;
• health condition;
• severity of disease;
• risk associated with participation;
• degree of disability;
• duration of injury;
• loss of wages;
• causal connection with the trial;
• seriousness of the adverse event.

The Seventh Schedule therefore attempts to introduce a more standardized approach rather than leaving every compensation decision entirely to subjective judicial assessment.

11. Procedure for a Clinical-Trial Injury Claim

A simplified framework is:

Step 1 — Adverse event occurs

The participant suffers an injury or dies.

↓

Step 2 — Reporting

The investigator, sponsor and Ethics Committee undertake the required reporting and assessment.

↓

Step 3 — Causality assessment

The authorities determine whether the injury/death is related to the clinical trial.

↓

Step 4 — Expert assessment

In death cases, the regulatory framework provides for expert examination concerning the cause and quantum of compensation.

↓

Step 5 — Regulatory determination

The Central Licensing Authority/appropriate authority determines the compensation in accordance with the applicable procedure.

↓

Step 6 — Payment

The sponsor or representative must pay the prescribed compensation.

12. Role of the Sponsor

The sponsor has a central responsibility.

The sponsor may be:

• pharmaceutical company;
• biotechnology company;
• research institution;
• academic institution;
• other entity responsible for the clinical investigation.

The sponsor is expected to provide the necessary undertaking concerning compensation.

The Rules specifically require the sponsor to undertake to provide compensation where a participant becomes entitled to it.

13. Role of the Investigator

The investigator is responsible for conducting the trial according to the approved protocol.

Potential problems include:

• protocol deviation;
• failure to monitor the participant;
• failure to report serious adverse events;
• negligent administration of the investigational product;
• inadequate emergency care;
• improper documentation.

If injury results from such conduct, the regulatory compensation framework may be engaged.

14. Role of the Ethics Committee

The Ethics Committee is an important safeguard.

Its responsibilities include consideration of:

• participant safety;
• informed consent;
• risk-benefit assessment;
• serious adverse events;
• compensation issues.

The Committee's assessment can therefore become significant evidence in determining whether compensation is payable.

15. Importance of Informed Consent

Clinical-trial consent is much more than obtaining a signature.

A participant should understand:

• purpose of the trial;
• experimental nature of the intervention;
• foreseeable risks;
• possible benefits;
• alternative treatment;
• right to withdraw;
• compensation arrangements;
• medical treatment available in case of injury.

This principle is strongly supported by the Supreme Court's decision in Samira Kohli v. Dr. Prabha Manchanda.

16. Case Law 1 — Samira Kohli v. Dr. Prabha Manchanda

(2008) 2 SCC 1

Facts

The patient consented to a diagnostic procedure but, during the procedure, underwent a much more extensive surgery involving removal of reproductive organs.

She alleged that she had not provided valid consent for that additional procedure.

Supreme Court's ruling

The Supreme Court emphasized that a doctor must obtain real and valid consent before treatment.

The consent should be based upon adequate information concerning the nature and purpose of the treatment, material risks and alternatives.

Relevance to clinical trials

Clinical-trial participants are exposed to experimental risks.

Therefore, informed consent becomes particularly important.

A consent document that merely says:

“There may be risks”

may not necessarily satisfy the ethical/legal requirements if material information concerning the trial has been withheld.

Principle

Consent must be informed, voluntary and based upon adequate disclosure.

17. Case Law 2 — Jacob Mathew v. State of Punjab

(2005) 6 SCC 1

Facts

The case concerned alleged medical negligence arising from the treatment of a patient in a hospital.

Supreme Court's ruling

The Court examined the distinction between:

• ordinary medical error;
• professional negligence;
• civil liability;
• criminal negligence.

It emphasized that a medical professional is judged against the standard of a reasonably competent practitioner possessing the ordinary skill expected of that profession.

Relevance to clinical trials

A clinical investigator does not become liable merely because an adverse event occurs.

The claimant may need to distinguish:

known/accepted risk of experimental treatment

from

negligent conduct in conducting the trial.

For example:

• proper protocol + known adverse reaction ≠ automatically negligence;
• protocol violation + negligent administration + resulting injury → potentially actionable.

Principle

An adverse medical outcome by itself does not establish professional negligence.

18. Case Law 3 — Kusum Sharma v. Batra Hospital & Medical Research Centre

(2010) 3 SCC 480

Facts

The case involved allegations of medical negligence and deficiency in medical services.

Supreme Court's approach

The Court discussed the standard of care applicable to medical professionals and emphasized that negligence must be assessed with reference to the circumstances and the standard of a reasonably competent professional.

Relevance

Clinical trials involve specialized medical and scientific procedures.

A court therefore should not decide scientific negligence simply through hindsight.

Relevant evidence may include:

• clinical protocol;
• medical literature;
• expert opinion;
• regulatory standards;
• accepted clinical practice.

Principle

Clinical-trial conduct should be evaluated according to the appropriate professional and scientific standard rather than hindsight alone.

19. Case Law 4 — Spring Meadows Hospital v. Harjol Ahluwalia

(1998) 4 SCC 39

Facts

A child suffered severe brain damage after an injection was improperly administered and there was delay in resuscitation.

The National Consumer Disputes Redressal Commission awarded substantial compensation.

The Supreme Court upheld the finding of negligence and recognized compensation for both the injured child and the parents' mental agony.

Relevance to clinical trials

The case demonstrates that compensation may include more than immediate medical expenditure.

Depending upon the legal route, compensation can account for:

• permanent disability;
• future care;
• mental suffering;
• financial consequences;
• loss of quality of life.

Principle

Serious medical injury can justify compensation extending beyond immediate treatment expenses.

20. Case Law 5 — Achutrao Haribhau Khodwa v. State of Maharashtra

(1996) 2 SCC 634

Facts

A patient undergoing sterilization surgery suffered harm because a surgical mop/towel was left inside her abdomen.

Supreme Court's ruling

The Court found negligence and recognized the State's liability for negligence committed by medical personnel in a government hospital.

The Court emphasized that a doctor owes a duty to exercise reasonable skill, knowledge and care.

Relevance

Clinical trials involve complex procedures where failure to follow the protocol can produce serious injury.

Thus, evidence of:

• protocol violation;
• inadequate procedure;
• failure to follow safety requirements

can become highly important.

Principle

A healthcare institution may be liable for negligent acts committed by its medical personnel in the course of professional duties.

21. Case Law 6 — Indian Medical Association v. V.P. Shantha

(1995) 6 SCC 651

Issue

The Supreme Court considered whether medical services fall within the scope of consumer protection law.

Decision

The Court held that medical services rendered for consideration generally fall within the consumer-protection framework, subject to the distinctions recognized by the Court concerning free services and other categories.

The case became foundational for medical-negligence claims under consumer law.

Relevance to clinical trials

A clinical-trial participant may potentially have multiple legal relationships:

• participant–sponsor;
• participant–investigator;
• patient–hospital;
• participant–research institution.

Where the statutory requirements for consumer jurisdiction are satisfied, medical-service principles may become relevant.

However, one should not automatically assume that every clinical-trial participant is a “consumer” for every aspect of the trial. The precise contractual and statutory circumstances matter.

22. Case Law 7 — Paschim Banga Khet Mazdoor Samity v. State of West Bengal

(1996) 4 SCC 37

Facts

A seriously injured person was taken to several government hospitals but was denied timely treatment because of inadequate facilities.

Supreme Court's ruling

The Court held that failure by government hospitals to provide timely medical treatment violated Article 21.

It also held that compensation could be awarded for violation of constitutional rights.

Relevance

The case is important where clinical research is conducted in a public institution.

If a State institution violates constitutional rights through serious failures in medical care, a public-law compensation remedy may potentially become relevant.

Principle

The right to life includes access to adequate medical treatment, and serious State violations may justify constitutional compensation.

23. Case Law 8 — V. Krishnakumar v. State of Tamil Nadu

(2015) 7 SCC 313 / AIR 2015 SC 2836

This case concerned medical negligence in a government hospital and compensation for the consequences suffered by the patient.

The Supreme Court examined the appropriate approach to compensation and recognized the significance of long-term consequences, including financial burdens and care requirements.

Relevance to clinical trials

Clinical-trial injuries can similarly create long-term consequences:

• permanent disability;
• loss of earning capacity;
• continuing medical treatment;
• rehabilitation;
• caregiver costs.

The case therefore provides useful guidance on the broader concept of compensatory relief.

24. Case Law 9 — Parmanand Katara v. Union of India

(1989) 4 SCC 286

The Supreme Court emphasized the paramount importance of preserving human life and the duty to provide immediate medical assistance.

Although this was not a clinical-trial case, its constitutional principle is relevant where a trial participant suffers an emergency.

The clinical-research environment cannot justify failure to provide emergency medical treatment.

Principle

Participation in research does not diminish the participant's fundamental right to life and emergency medical care.

25. Case Law Summary

26. Important Distinction: Regulatory Compensation vs Civil Damages

This distinction is extremely important for examinations.

27. Is Every Death During a Clinical Trial Compensable?

No—not automatically.

This is a critical point.

The mere fact that:

“A participant died while enrolled in a clinical trial”

does not necessarily establish that the death was caused by the trial.

The relevant question is whether the death qualifies as clinical-trial-related death under the applicable regulatory provisions.

The regulatory framework specifically identifies circumstances that qualify for compensation.

Therefore:

Temporal connection ≠ necessarily causal connection.

28. Causation

Causation is one of the most difficult aspects.

Consider:

A patient with advanced cancer enters a Phase III trial and dies two weeks later.

The fact that the patient was participating in the trial does not itself prove:

investigational drug → death.

The authorities may have to consider:

• underlying disease;
• co-morbidities;
• investigational drug;
• concomitant medication;
• clinical procedure;
• placebo;
• protocol deviation;
• medical management.

This is why serious-adverse-event investigation is essential.

29. Scientific Evidence

Clinical-trial compensation claims may require highly specialized evidence.

Relevant material can include:

• clinical-trial protocol;
• informed-consent document;
• investigator's records;
• adverse-event reports;
• medical records;
• laboratory results;
• pharmacovigilance data;
• Ethics Committee findings;
• expert committee reports;
• causality assessments;
• regulatory correspondence.

The court or regulator may need to distinguish between:

expected risk

and

compensable trial-related injury.

30. Informed Consent Does Not Automatically Waive Compensation

This is another important principle.

Suppose the consent form states:

“The drug may cause serious adverse effects.”

The participant's signature does not necessarily mean that the sponsor is immune from liability.

Consent primarily establishes that the participant knowingly agreed to participate.

It does not necessarily authorize:

• negligent conduct;
• protocol violations;
• scientific misconduct;
• defective procedures;
• concealment of material information.

The reasoning of Samira Kohli concerning valid and informed consent is therefore highly relevant.

31. Compensation for Loss of Earning Capacity

Where a participant suffers permanent disability, compensation may have to consider:

• age;
• occupation;
• income;
• future earning capacity;
• degree of disability;
• medical expenses;
• rehabilitation;
• attendant/caregiver costs.

However, clinical-trial regulatory compensation may operate through its own prescribed formula rather than the conventional multiplier methodology used in tort claims.

32. Compensation for Mental Suffering

Where an ordinary civil/consumer negligence action is available, compensation may potentially include:

• pain and suffering;
• mental agony;
• loss of amenities;
• loss of quality of life.

Spring Meadows Hospital is particularly useful for this principle because the Court recognized compensation associated with the severe consequences of medical negligence and the mental agony suffered by parents.

33. Who Is Responsible?

Potentially relevant parties include:

Sponsor

Primary responsibility under the clinical-trial compensation framework.

Investigator

Potential liability for:

• negligence;
• protocol violations;
• misconduct.

Research institution

May be responsible under applicable contractual, tortious, consumer or institutional principles.

Hospital

Potential liability for negligent medical services.

CRO

A Contract Research Organization may have contractual and regulatory responsibilities depending on its role.

Ethics Committee

Its regulatory/ethical role must be distinguished from ordinary tort liability; mere participation in oversight does not automatically make it liable for every adverse event.

34. Failure to Pay Compensation

The regulatory framework contains enforcement mechanisms.

If a sponsor fails to provide required medical management or compensation, regulatory authorities may take action, including measures affecting the sponsor's ability to conduct clinical trials.

Thus:

Clinical-trial compensation is not merely a private contractual promise between the sponsor and participant.

It forms part of the regulatory structure governing clinical research.

35. Insurance

Sponsors commonly need appropriate financial arrangements to cover potential clinical-trial risks.

Insurance arrangements may address:

• participant injury;
• death;
• trial-related liability.

The Ethics Committee may also consider insurance/compensation arrangements during review of the study.

Insurance, however, generally does not eliminate the sponsor's underlying regulatory responsibility.

36. Special Importance of Vulnerable Participants

Extra care is necessary where participants include:

• children;
• persons lacking decision-making capacity;
• economically vulnerable persons;
• persons with serious diseases;
• pregnant participants;
• persons unable to understand the trial information.

Consent requirements and ethical safeguards become especially important.

37. Constitutional Dimension

Clinical-trial compensation can also be viewed through Article 21 of the Constitution.

Article 21 protects life and personal liberty.

The Supreme Court's medical-rights jurisprudence has repeatedly emphasized:

• preservation of life;
• access to medical treatment;
• bodily integrity;
• informed decision-making.

Paschim Banga demonstrates that serious State failures in medical care can produce a constitutional compensation remedy.

Thus, clinical research must operate within the broader constitutional framework protecting human dignity and bodily autonomy.

38. Major Defences in Clinical-Trial Compensation Claims

A sponsor or investigator may argue:

1. No causal relationship

The injury resulted from the underlying disease.

2. Known natural progression

The participant's condition deteriorated independently of the trial.

3. No protocol violation

The trial was conducted exactly as approved.

4. Proper informed consent

The participant was informed of material risks.

5. Compliance with medical standards

The investigator acted according to accepted scientific practice.

6. Alternative cause

Another medicine or medical condition caused the injury.

7. Regulatory compliance

The sponsor complied with applicable clinical-trial requirements.

But regulatory compliance does not necessarily provide absolute immunity from independent negligence or other legal claims.

39. Challenges in Clinical Trial Compensation Claims

A. Causation

Determining whether the injury resulted from the investigational product can be scientifically difficult.

B. Pre-existing disease

Many trial participants already suffer serious medical conditions.

C. Multiple medicines

Concomitant medication can complicate causation.

D. Informed consent

A participant may have signed a form without genuinely understanding the risks.

E. Quantum

The regulatory formula and ordinary damages principles may produce different compensation approaches.

F. Delay

Long regulatory investigations can create hardship for injured participants and families.

G. Expert evidence

Scientific disputes require specialized expertise.

40. Example

Suppose a pharmaceutical company conducts a Phase III trial for a new cardiac drug.

A participant suffers permanent cardiac injury.

Scenario 1

The injury is a known adverse effect of the investigational drug.

Potential clinical-trial compensation: Yes, if the regulatory criteria are satisfied.

Scenario 2

The investigator administered the wrong dosage contrary to the protocol.

Potential liability: Clinical-trial compensation + possible negligence liability.

Scenario 3

The participant suffered an unrelated stroke caused by a pre-existing condition.

Potential compensation: Not necessarily payable merely because the participant was enrolled in the trial.

Scenario 4

The participant was given placebo while standard care that should have been provided under the protocol was withheld.

Potential compensation: The regulatory framework expressly recognizes specified placebo-related circumstances.

41. Exam-Oriented Legal Test

When answering a clinical-trial compensation problem, follow this sequence:

1. Identify the injury

Was it:

• death?
• permanent disability?
• temporary injury?
• medical complication?

2. Identify the legal framework

Apply:

• NDCTR 2019;
• Contract Act where relevant;
• Consumer Protection law where applicable;
• constitutional principles;
• tort/medical-negligence principles.

3. Determine causation

Was the injury actually related to:

• investigational product?
• protocol violation?
• clinical procedure?
• concomitant medication?
• placebo?
• negligence?

4. Determine responsible party

• sponsor;
• investigator;
• institution;
• hospital;
• CRO.

5. Determine quantum

Apply the relevant regulatory formula or ordinary compensation principles depending upon the legal route.

6. Consider additional remedies

• medical management;
• compensation;
• rehabilitation;
• damages;
• constitutional relief;
• consumer remedy;
• regulatory action.

42. Key Principles From the Case Law

Principle 1

Clinical-trial participation does not waive fundamental rights.

Principle 2

Consent must be informed and voluntary.

Principle 3

A known adverse event does not automatically establish negligence.

Principle 4

Protocol violations can be legally significant.

Principle 5

Hospitals and institutions can be liable for negligent conduct of their personnel where the law so provides.

Principle 6

Serious medical injury can justify compensation beyond immediate medical expenses.

Principle 7

Article 21 can support compensation where State medical failures violate fundamental rights.

Principle 8

Clinical-trial compensation operates through a specialized regulatory framework and should not be confused with ordinary medical-negligence damages.

43. Case-Law Table for Examination

44. Conclusion

Clinical Trial Compensation Claims occupy a unique position between medical law, pharmaceutical regulation, consumer protection, tort law, constitutional rights and bioethics.

India has moved substantially beyond a purely negligence-based model. The New Drugs and Clinical Trials Rules, 2019 create a specific regulatory mechanism under which qualifying clinical-trial injuries and deaths can attract compensation from the sponsor, with prescribed procedures and formulas.

The central legal principles can be summarized as:

Participation in a clinical trial must be voluntary and informed; research-related injury must receive appropriate medical management; qualifying trial-related injury or death can attract statutory compensation; and negligence, protocol violation, misconduct or violation of patient rights may create additional legal consequences.

For an examination, the most important authorities to remember are Samira Kohli, Jacob Mathew, Kusum Sharma, Spring Meadows Hospital, Achutrao Haribhau Khodwa, Indian Medical Association v. V.P. Shantha, Paschim Banga Khet Mazdoor Samity, and V. Krishnakumar.

The most important statutory point is that the NDCTR 2019 compensation mechanism is specialized and should not be confused with ordinary medical-negligence compensation. That distinction is crucial when determining causation, liability, quantum and the appropriate forum.